

LIST OF FIGURES

Figure 1.1: Formation of fibrin from fibrinogen.....	27
Figure 1.2: Structure of Nattokinase	31
Figure 1.3: Structure of streptokinase	32
Figure 1.4: Structure of Urokinase	34
Figure 1.5: Structure of tissue plasminogen activator (t-PA)	34
Figure 1.6: Schematic representation of plasmin formation through <i>in vivo</i> processing	37
Figure 1.7: Schematic representation of fibrinolysis by plasmin	38
Figure 3.1: Intravenous administration of purified fibrin(ogen)olytic/ fibrinolytic enzyme at a dose of 10 mg/kg in tail vein rats.....	81
Figure 3.2: Echocardiogram of control as well as treated rats after 14 days of intravenous administration of purified fibrin(ogen)olytic/ fibrinolytic enzyme/ PBS (control) at a dose of 10 mg/kg in tail vein rats	81
Figure 3.3: Measurement of the PenH value (respiratory system) by whole body plethysmograph after 14 days of intravenous administration of purified fibrin(ogen)olytic/ fibrinolytic enzyme or PBS (control) at a dose of 10 mg/kg in tail vein rat.....	82
Figure 3.4: Collection of blood sample from control and treated rats by mechanical disruption of retro orbital sinus.....	82
Figure 3.5: Collection of blood sample from control and treated rats for hematological (blue) and serum profile analysis (red)	83
Figure 3.6: BIOPAC system was used to capture rat before intravenous administration of purified enzymes in tail vein.	85
Figure 3.7: Intravenous administration of purified enzyme in carrageenan induced rat tail vein.	85
Figure 4.1: Zone of hydrolysis around the FF01 bacterial colonies on fibrin agar medium	92

Figure 4.2: Pure culture morphology and gram staining of bacterial strains FF01 .	93
Figure 4.3: Phylogenetic relationships of strain FF01 and other closely related <i>Bacillus</i> species based on their 16S rDNA sequences	97
Figure 4.4: Phylogenetic relationships based on 16S-23S ISR sequences of strain FF01 and other closely related <i>Bacillus</i> species	99
Figure 4.5A: Purification of Bacethrombase from <i>Bacillus cereus</i> strain FF01 by hydrophobic interaction chromatography	100
Figure 4.5B: Purification of Bacethrombase from <i>Bacillus cereus</i> strain FF01 by gel-filtration chromatography on a Hi Load TM Superdex 75 pg 16/60 FPLC column.....	101
Figure 4.6: Determination of purity of Bacethrombase by SDS-PAGE (12.5%) analysis.....	102
Figure 4.7: MALDI-TOF-MS spectrum of Bacethrombase.	102
Figure 4.8: Secondary structure of native Bacethrombase by circular dichroism (CD) analysis	105
Figure 4.9: Determination of <i>K_m</i> and <i>V_{max}</i> values of Bacethrombase against V0882 by Lineweaver-Burk double reciprocal plot	106
Figure 4.10: Determination of <i>K_m</i> and <i>V_{max}</i> values of plasmin against V0882 by Lineweaver-Burk double reciprocal plot	107
Figure 4.11: Effect of Bacethrombase on extracellular membrane proteins	108
Figure 4.12: Effect of temperature on activity of Bacethrombase.....	109
Figure 4.13: Effect of temperature on Bacethrombase activity	109
Figure 4.14: Effect of substrate (fibrinogen) concentration on protease activity of Bacethrombase at 2.5 μ M to 58.5 μ M.	111
Figure 4.15: Plasminogen activation property of Bacethrombase	112
Figure 4.16: Determination of sialic acid content in Bacethrombase by 12.5% SDS-PAGE analysis under denaturation conditions	113
Figure 4.17A: A SDS-PAGE analysis of fibrinogen degradation by Bacethrombase	114

Figure 4.17B: SDS-PAGE analysis of fibrin degradation by Bacethrombase.....	115
Figure 4.18A: A comparison of fibrinogen degradation between plasmin and Bacethrombase under identical experimental conditions by RP-UHPLC analysis.....	116
Figure 4.18B: A comparison of fibrin degradation between plasmin and Bacethrombase under identical experimental conditions by RP-UHPLC analysis.....	117
Figure 4.19: A comparison of <i>in vitro</i> thrombolytic activity among Bacethrombase, plasmin and Streptokinase at 37 °C, pH 7.4, under identical experimental conditions.....	118
Figure 4.20: Cell cytotoxicity of Bacethrombase on Hela and HT29 cells	119
Figure 4.21A: A Dose-dependent platelet deaggregation by Bacethrombase	120
Figure 4.21B: Effect of Bacethrombase on collagen-induced platelet aggregation	121
Figure 4.21C: Dose-dependent inhibition of ADP-induced platelet aggregation by Bacethrombase	122
Figure 4.22: Effect of pre-incubation time (0 - 30 min) of Bacethrombase (0.1 µM) / platelet poor plasma (PPP) at 37 °C on Ca ²⁺ clotting time of PPP	123
Figure 4.23: A comparison of the dose-dependent anticoagulant activity among Bacethrombase, warfarin, heparin and plasmin under identical experimental conditions	124
Figure 4.24: Effect of Bacethrombase in inhibition of prothrombin activating property factor Xa.....	125
Figure 4.25: Interaction between Bacethrombase and fibrinogen/thrombin by fluorescence spectroscopy	126
Figure 4.26: Effect of pre-incubation of Bacethrombase with fibrinogen on fibrinogen clotting time of thrombin.....	127
Figure 4.27: Effect of i.v. injection of Bacethrombase on ECG of rats.....	129
Figure 4.28(A-H): Light microscopic observation of the effect of Bacethrombase (at a dose of 10 mg/kg) on different organs of treated rats	132

Figure 4.29: Determination of carrageenan-induced thrombus formation in rat tail	133
Figure 4.30: (a-f) Dose-dependent thrombolytic effect of Bacethrombase, streptokinase and plasmin.....	134
Figure 4.31: Effect of different concentrations of Bacethrombase on activated thromboplastin time (APTT) and prothrombin time (PT) of PPP	136
Figure 4.32: Assessment of thrombin time (TT) at various dosages of Bacethrombase.....	137
Figure 4.33: The <i>in vivo</i> dose-dependent defibrinogenating activity of Bacethrombase.....	138
Figure 4.34: Dose dependent <i>in vivo</i> anticoagulant action of Bacethrombase.	138
Figure 5.1: Zone of hydrolysis around the FF02B bacterial colonies on fibrin plate agar medium.....	145
Figure 5.2: Pure culture of colony morphology, Gram staining of bacterial strain FF02B.	148
Figure 5.3: Phylogenetic relationships of strain FF02B and other closely related <i>Brevibacillus</i> species based on partial 16S rDNA sequences.....	150
Figure 5.4: Phylogenetic relationships of strain FF02B and other closely related <i>Brevibacillus</i> species based on 16S-23S ISR homologous sequences..	153
Figure 5.5A: Purification of crude Brevithrombolase from <i>Brevibacillus brevis</i> strain FF02B by Hydrophobic interaction chromatography	154
Figure 5.5B: Purification of Brevithrombolase from <i>Brevibacillus brevis</i> strain FF02B by Gel-filtration chromatography	155
Figure 5.6: Determination of purity and molecular mass of Brevithrombolase by 12.5% SDS-PAGE analysis under reduced and non-reduced conditions.	156
Figure 5.7: MALDI-TOF-MS spectrum of Brevithrombolase.	156
Figure 5.8: Determination of secondary structure of native Brevithrombolase by circular dichroism (CD) analysis	159

Figure 5.9: Determination of Km and Vmax of Brevithrombolase by Lineweaver-Burk double reciprocal plot	160
Figure 5.10: Effect of temperature on Brevithrombolase activity. Values are mean of \pm SD of three replicates.....	161
Figure 5.11: Effect of pH on Brevithrombolase activity. Values are mean of \pm SD of three replicates.	161
Figure 5.12: Plasminogen activation property of Brevithrombolase	162
Figure 5.13: 15% SDS-PAGE (reducing conditions) analysis of native and deglycosylated Brevithrombolase.....	164
Figure 5.14: A comparison of fibrin degradation between 1.0 μ M of (A) Brevithrombolase, and (B) plasmin:	165
Figure 5.15: A comparison of fibrinolytic activity between plasmin and Brevithrombolase under identical conditions (37 °C, pH 7.4).....	166
Figure 5.16: Comparison of RP-UPLC elution profile of fibrin degradation products, generated by plasmin / Brevithrombolase, under identical experimental conditions.....	166
Figure 5.17: Cell cytotoxicity of Brevithrombolase on Hela and HT29 cells.	168
Figure 5.18: A comparison of the dose-dependent anticoagulant activity among Brevithrombolase, warfarin, heparin and plasmin under identical experimental conditions.....	169
Figure 5.19: Effect of pre-incubation (0–40 min) of Brevithrombolase/platelet poor plasma (PPP) on Ca ²⁺ clotting time of PPP.	170
Figure 5.20: Effect of Brevithrombolase in FXa inhibition as analyzed by 12.5% SDS-PAGE.	171
Figure 5.21: Dose-dependent inhibition of amidolytic activity of thrombin by Brevithrombolase.....	172
Figure 5.22: Effect of Brevithrombolase (0.05 -1 μ M) on fibrinogen clotting time of thrombin.....	173
Figure 5.24: Kinetics of thrombin degradation by Brevithrombolase at 37 °C.....	174

Figure 5.25: Effect of <i>i.v</i> injection of Brevithrombolase (10mg/kg) on ECG of treated rat.	177
Figure 5.26(A-H): Light microscopic observation of the effect of Brevithrombolase (at a dose of 10 mg/kg) on different organs of treated rats.	179
Figure 5.27: The <i>in vivo</i> effect of Brevithrombolase on tail bleeding and blood clotting time in Wistar strain albino rats.....	179
Figure 5.28: Dose-dependent thrombolytic effect of Brevithrombolase	180
Figure 5.29: Dose dependent activated partial thromboplastin time (APTT) and prothrombin time (PT) of Brevithrombolase	182
Figure 5.30: Dose-dependent thrombin time (TT) of Brevithrombolase-treated rats.	183
Figure 5.31: The <i>in vivo</i> dose-dependent fibrin(ogen)olytic activity of Brevithrombolase.....	184
Figure 5.32: Dose-dependent <i>in vivo</i> anticoagulant activity of Brevithrombolase..	185